Brind.
  1. Anixa Biosciences announced developments regarding its CER-T cancer treatment, collaborating with Cleveland Clinic, at a conference in New York City on September 2, 2025.
  2. Anixa Biosciences and Cleveland Clinic are developing a vaccine portfolio and ovarian cancer immunotherapy program.

Anixa collaborated with Cleveland Clinic on vaccine development, with Amit Kumar serving as CEO of Anixa.

5 reports, 1 independent Updated Sep 21
Gone quiet
Reports
5
Developments
3
Repetition
40%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Anixa collaborated with Cleveland Clinic on vaccine development, with Amit Kumar serving as CEO of Anixa.

Who's involved

What this event is mainly about
CompanyCleveland Clinic

How it developed

Newest first. Tap a step to see who reported it.
  1. Anixa and Cleveland Clinic are collaborating on vaccine development.1 source
  2. Anixa's patent received Notice of Allowance from CIPO and is exclusively licensed by Cleveland Clinic.1 source
  3. Amit Kumar, CEO of Anixa, detailed the company's use of CAR-T and CER-T technology.

Keep exploring

Part of

Anixa Biosciences and Cleveland Clinic are developing a vaccine portfolio and ovarian cancer immunotherapy program. All 2 developments

Within Anixa Biosciences announced developments regarding its CER-T cancer treatment, collaborating with Cleveland Clinic, at a conference in New York City on September 2, 2025.

The entities involved

Coverage

Newest first; wire copies grouped
  • PR NewswireAnixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial Progress Follows Positive Immune Response Observed in Phase 1 Study SA
  • PR NewswireAnixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology Patent Strengthens International Protection for First-of
  • PR NewswireAnixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s Patent Expands Immunogenic Coverage of α-Lactalbumin-Based Vaccine Platform Technology Addresses Sub
  • Unknown outlet
1 more outlet ran the same wire story